These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24481385)

  • 1. Incidence of maternal sensitisation to Rh(D) in Christchurch, New Zealand and reasons for prophylaxis failures.
    Badami KG; Parker J; Kenny A; Warrington S
    N Z Med J; 2014 Jan; 127(1388):40-6. PubMed ID: 24481385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.
    Pilgrim H; Lloyd-Jones M; Rees A
    Health Technol Assess; 2009 Feb; 13(10):iii, ix-xi, 1-103. PubMed ID: 19210896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of maternal alloimmunisation to Rh D in Northern Ireland.
    McCauley CJ; Morris K; Maguire K
    Transfus Med; 2017 Apr; 27(2):132-135. PubMed ID: 28101958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical validation of routine antenatal anti-D prophylaxis questions the modelling predictions adopted by NICE for Rhesus D sensitisation rates: results of a longitudinal study.
    Mackenzie IZ; Roseman F; Findlay J; Thompson K; McPherson K
    Eur J Obstet Gynecol Reprod Biol; 2008 Jul; 139(1):38-42. PubMed ID: 18243487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hemolytic disease of the newborn has not vanished from Finland--routine protection of RhD negative mothers during pregnancy is justifiable].
    Sainio S; Kuosmanen M
    Duodecim; 2012; 128(2):151-7. PubMed ID: 22372070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time points and risk factors for RhD immunizations after the implementation of targeted routine antenatal anti-D prophylaxis: A retrospective nationwide cohort study.
    Jernman R; Isaksson C; Haimila K; Kuosmanen M; Mäkikallio-Anttila K; Toivonen S; Ordén MR; Sulin K; Tihtonen K; Vääräsmäki M; Sainio S
    Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1868-1875. PubMed ID: 34157128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of new recommendations on routine antenatal prevention of rhesus immunization: an appraisal based on a retrospective analysis of all cases observed in two French administrative areas of 3 million inhabitants.
    Boulet S; Krause C; Tixier H; Bardou M; Sagot P
    Eur J Obstet Gynecol Reprod Biol; 2009 Sep; 146(1):65-70. PubMed ID: 19482403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Red blood cell iso-immunisation in the Wellington area of New Zealand: the case for antenatal prophylaxis.
    Tuohy JF; Sangalli M; Kim L
    Aust N Z J Obstet Gynaecol; 2004 Oct; 44(5):458-9. PubMed ID: 15387870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the immunologic basis of Rh immune globulin (anti-D) prophylaxis.
    Kumpel BM
    Transfusion; 2006 Sep; 46(9):1652-6. PubMed ID: 16965599
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prevention of fetomaternal rhesus-D allo-immunization. Practical aspects].
    Cortey A; Brossard Y
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S123-1S130. PubMed ID: 16495838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compliance with routine antenatal rhesus D prophylaxis and the impact on sensitisations: observations over 14 years.
    MacKenzie IZ; Findlay J; Thompson K; Roseman F
    BJOG; 2006 Jul; 113(7):839-43. PubMed ID: 16827770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
    Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
    BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current viewpoints in the anti-D prevention of rhesus alloimmunization in the pregnant woman and of hemolytic disease of the newborn infant (a review of the literature)].
    Spasova K; Vŭlcheva B
    Akush Ginekol (Sofiia); 1986; 25(3):84-90. PubMed ID: 3019168
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-D in Rh(D)-negative pregnant women: are at-risk pregnancies and deliveries receiving appropriate prophylaxis?
    Koby L; Grunbaum A; Benjamin A; Koby R; Abenhaim HA
    J Obstet Gynaecol Can; 2012 May; 34(5):429-435. PubMed ID: 22555135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy.
    Koelewijn JM; de Haas M; Vrijkotte TG; Bonsel GJ; van der Schoot CE
    Transfusion; 2008 Aug; 48(8):1721-9. PubMed ID: 18507749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rh D foeto-maternal alloimmunization prophylaxis with anti-D immunoglobulins reviewed in the era of foetal RHD genotyping.
    Minon JM; Gerard Ch; Schaaps JP; Foidart JM
    Acta Clin Belg; 2009; 64(3):195-202. PubMed ID: 19670558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program.
    Tiblad E; Taune Wikman A; Ajne G; Blanck A; Jansson Y; Karlsson A; Nordlander E; Holländer BS; Westgren M
    PLoS One; 2013; 8(8):e70984. PubMed ID: 23940682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adverse effects and patient information].
    Cortey A; Brossard Y
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S112-1S118. PubMed ID: 16495836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of the efficacy of different methods for the prevention of anti-D allo-immunization during pregnancy: targeted strategy limited to risk situations or associated with systematic prevention in the 3rd trimester].
    Parant O
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S93-1S103. PubMed ID: 16495834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring and treatment of anti-D in pregnancy.
    Bettelheim D; Panzer S; Reesink HW; Csapo B; Pessoa C; Guerra F; Wendel S; Calda P; Sprogøe U; Dziegiel M; Aitokallio-Tallberg A; Koskinen S; Kuosmanen M; Legler TJ; Stein W; Villa S; Villa MA; Trespidi L; Acaia B; Vandenbussche FP; Brand A; de Haas M; Kanhai HH; Gounder D; Flanagan P; Donegan R; Parry E; Sefonte C; Skulstad SM; Hervig T; Flesland Ø; Zupańska B; Uhrynowska M; Lapaire O; Zhong XY; Holzgreve W
    Vox Sang; 2010 Aug; 99(2):177-92. PubMed ID: 20331536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.